Efficacy and safety ofTafamidis were investigated in the ATTR-ACT trial, which investigated both typesof transthyretin amyloid cardiomyopathy and showed that Tafamidis was associatedwith a reduction in all-cause mortality, hospitalizations due to cardiovascularevents and in the decline of functional capacity and quality of life [33]. This evidence concerns the gene TTR and cardiac amyloidosis.